CME/CE

Host: Ayse Tuba Kendi, MD Guest: A. Oliver Sartor, MD Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the t...

Host: Ayse Tuba Kendi, MD Guest: A. Oliver Sartor, MD Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the t...

Host: William Mencia, MD, FACEHP, CHCP Guest: Julie Blatt, MD Guest: Taizo Nakano, MD PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations var...

Host: William Mencia, MD, FACEHP, CHCP Guest: Julie Blatt, MD Guest: Taizo Nakano, MD PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations var...

Guest: Sara A. Hurvitz, MD, FACP HER2-Directed ADCs in Breast Cancer

Guest: Sara A. Hurvitz, MD, FACP HER2-Directed ADCs in Breast Cancer

Guest: Arlene B. Chapman, MD Guest: Michel Chonchol, MD This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.

Host: Jennifer Caudle, DO Guest: Mikkael A. Sekeres, MD, MS Guest: Sara M. Tinsley, PhD, ARNP, AOCNP Please note: This activity is no longer available for continuing education credit. There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia...

Guest: Arlene B. Chapman, MD Guest: Michel Chonchol, MD This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.

Host: Jennifer Caudle, DO Guest: Mikkael A. Sekeres, MD, MS Guest: Sara M. Tinsley, PhD, ARNP, AOCNP Please note: This activity is no longer available for continuing education credit. There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia...

Guest: Michel Chonchol, MD Guest: Frederic Rahbari-Oskoui, MD, MSc This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.

Guest: Michel Chonchol, MD Guest: Frederic Rahbari-Oskoui, MD, MSc This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.

Guest: Matthew B. Lanktree, MD, PhD Guest: Neera Dahl, MD, PhD This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.

Guest: Matthew B. Lanktree, MD, PhD Guest: Neera Dahl, MD, PhD This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.

Guest: Arlene B. Chapman, MD Guest: Matthew B. Lanktree, MD, PhD This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.

Guest: Arlene B. Chapman, MD Guest: Matthew B. Lanktree, MD, PhD This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.

Guest: Jimmy T. Lee, MD Guest: Arlene B. Chapman, MD This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Guest: Jimmy T. Lee, MD Guest: Arlene B. Chapman, MD This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Host: Robert A. Hauser, MD, MBA, FAAN Guest: Stuart H. Isaacson, MD Please note: This activity is no longer available for continuing education credit. This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease. You can access the Clinical Compendium for Novel Therapies to Manage OFF Episodes in Pa...

Host: Robert A. Hauser, MD, MBA, FAAN Guest: Stuart H. Isaacson, MD Please note: This activity is no longer available for continuing education credit. This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease. You can access the Clinical Compendium for Novel Therapies to Manage OFF Episodes in Pa...

Host: Mikhail Kosiborod, MD Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalem...

Host: Mikhail Kosiborod, MD Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalem...

Guest: David P. Hudesman, MD Please note: This activity is no longer available for continuing education credit. It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In thi...

Guest: Anita Afzali MD, MPH, FACG, AGAF Please note: This activity is no longer available for continuing education credit. The management of IBD remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this program, Dr. Anita Afzali presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive...

Guest: David P. Hudesman, MD Please note: This activity is no longer available for continuing education credit. It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In thi...